Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4764MR)

This product GTTS-WQ4764MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4764MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6586MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ10473MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ11984MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ14708MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SEG101
GTTS-WQ2107MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ11553MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGA031
GTTS-WQ15050MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SRF-231
GTTS-WQ13070MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-00547659
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW